⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2707394 | 1.00 | — | — | |
| SCHEMBL3540638 | 0.97 | — | — | |
| SCHEMBL3551279 | 0.97 | ALDH1A1 (0.32) | — | |
| SCHEMBL3548232 | 0.97 | ALDH1A1 (0.32) | — | |
| SCHEMBL3551062 | 0.97 | ALDH1A1 (0.32) | — | |
| SCHEMBL3547678 | 0.97 | ALDH1A1 (0.32) | — | |
| SCHEMBL3544913 | 0.97 | ALDH1A1 (0.32) | — | |
| SCHEMBL37418 | 0.92 | — | — | |
| SCHEMBL3967620 | 0.92 | — | — | |
| SCHEMBL8357828 | 0.92 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 840 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3984994-B1 | SUBSTITUTED PIPERIDINE COMPOUND AS OREXIN TYPE 2 AGONIST FOR THE TREATMENT OF NARCOLEPSY | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-03 | — | — | EP | claimed |
| US-20240199584-A1 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2024-06-20 | — | — | US | claimed |
| WO-2024114814-A1 | JAK INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | ONQUALITY PHARMACEUTICALS CHINA LTD (CN) | 2024-06-06 | — | — | WO | claimed |
| US-20240182406-A1 | COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | UNIVERSITAT DE BARCELONA (ES) | 2024-06-06 | — | — | US | claimed |
| WO-2024040109-A2 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-02-22 | — | — | WO | claimed |
| EP-4313947-A1 | COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | Universitat de Barcelona (ES) | 2024-02-07 | — | — | EP | claimed |
| EP-3810572-B1 | POLYCYCLIC COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | UNIV BARCELONA (ES) | 2023-11-15 | — | — | EP | claimed |
| EP-3609883-B1 | FLUORINE-SUBSTITUTED INDAZOLE COMPOUNDS AND USES THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2022-06-29 | — | — | EP | claimed |
| EP-3984994-A1 | SUBSTITUTED PIPERIDINE COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2022-04-20 | — | — | EP | claimed |
| CN-114181136-A | Substituted piperidine compounds and uses thereof | 武田药品工业株式会社 | 2022-03-15 | — | — | CN | claimed |
| WO-2003082290-A1 | 4-(N-PHENYLAMINO)-QUINAZOLINES / QUINOLINES AS TYROSINE KINASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-10-09 | — | — | WO | claimed |
| WO-2003053957-A1 | BENZHYDRYL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (US) | 2003-07-03 | — | — | WO | claimed |
| US-20030119827-A1 | Novel nitriles useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-06-26 | — | — | US | claimed |
| WO-2002100849-A2 | NOVEL NITRILES USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2002-12-19 | — | — | WO | claimed |
| JP-H09501913-A | — | — | 1997-02-25 | — | — | JP | claimed |
| EP-0738154-A1 | N-TERMINUS MODIFIED ANALOGS OF LHRH | Abbott Laboratories (US) | 1996-10-23 | — | — | EP | claimed |
| EP-0738154-A4 | N-TERMINUS MODIFIED ANALOGS OF LHRH | ABBOTT LAB (US) | 1996-04-12 | — | — | EP | claimed |
| US-5502035-A | N-terminus modified analogs of LHRH | TAP HOLDINGS INC. (US) | 1996-03-26 | — | — | US | claimed |
| WO-1995004541-A1 | N-TERMINUS MODIFIED ANALOGS OF LHRH | ABBOTT LABORATORIES (US) | 1995-02-16 | — | — | WO | claimed |
| EP-0110405-B1 | ANTIINFLAMMATORY/ANTIALLERGIC COMPOUNDS | RORER INTERNATIONAL (OVERSEAS) INC. (a Delaware corporation) (US) | 1990-12-27 | — | — | EP | claimed |